I agree that this site is using cookies. You can find further informations here.
X
Corash, L.
197  results:
Search for persons X
?
1

P‐TS‐76 | Safety and Efficacy of Amotosalen‐UVA Pathogen Re..:

Corash, L. ; Daskalakis, M. ; Mcdougall, J....
Transfusion.  63 (2023)  S5 - p. , 2023
Link: https://doi.org/10.1111/..
 
?
2

P‐TS‐24 | Design of ReCePI, a Randomized, Double‐Blinded, P..:

Benjamin, R. ; Pitman, J. ; Corash, L...
Transfusion.  63 (2023)  S5 - p. , 2023
Link: https://doi.org/10.1111/..
 
?
3

Characterization of efficacy and safety of pathogen inactiv..:

Herbrecht, R. ; Ojeda‐Uribe, M. ; Kientz, D....
Vox Sanguinis.  113 (2018)  5 - p. 459-467 , 2018
Link: https://doi.org/10.1111/..
 
?
4

Patient outcomes and amotosalen/UVA‐treated platelet utiliz..:

Nussbaumer, W. ; Amato, M. ; Schennach, H....
Vox Sanguinis.  112 (2017)  3 - p. 249-256 , 2017
Link: https://doi.org/10.1111/..
 
?
5

Red blood cell concentrates treated with the amustaline (S‐..:

Cancelas, J. A. ; Gottschall, J. L. ; Rugg, N....
Vox Sanguinis.  112 (2017)  3 - p. 210-218 , 2017
Link: https://doi.org/10.1111/..
 
?
6

A prospective, active haemovigilance study with combined co..:

Knutson, F. ; Osselaer, J. ; Pierelli, L....
Vox Sanguinis.  109 (2015)  4 - p. 343-352 , 2015
Link: https://doi.org/10.1111/..
 
?
7

Diverses formes de plasma thérapeutique traité photochimiqu..:

Payrat, J.-M. ; Erickson, A. ; Holtan, M...
Transfusion Clinique et Biologique.  22 (2015)  4 - p. 227-228 , 2015
Link: https://doi.org/10.1016/..
 
?
8

Pathogen inactivation of plasma components:

Corash, L. ; Stassinopoulos, A.
Vox Sanguinis.  102 (2011)  2 - p. 178-179 , 2011
Link: https://doi.org/10.1111/..
 
?
9

Monitoring photochemical pathogen inactivation treatment us..:

Isola, H. ; Brandner, D. ; Cazenave, J.-P...
Vox Sanguinis.  99 (2010)  4 - p. 402-402 , 2010
Link: https://doi.org/10.1111/..
 
?
10

INTERCEPT plasma: comparability with conventional fresh-fro..:

Irsch, J. ; Pinkoski, L. ; Corash, L..
Vox Sanguinis.  98 (2010)  1 - p. 47-55 , 2010
Link: https://doi.org/10.1111/..
 
?
11

An active haemovigilance programme characterizing the safet..:

Osselaer, J. C. ; Cazenave, J. P. ; Lambermont, M....
Vox Sanguinis.  94 (2008)  4 - p. 315-323 , 2008
Link: https://doi.org/10.1111/..
 
?
12

Therapeutic efficacy of pooled buffy‐coat platelet componen..:

Van Rhenen, D. J. ; Gulliksson, H. ; Cazenave, J. P....
Transfusion Medicine.  14 (2004)  4 - p. 289-295 , 2004
Link: https://doi.org/10.1111/..
 
?
13

107Prevention of platelet TA-GVHD by use of intercept blood..:

Lin, L. ; Corash, L.
Biology of Blood and Marrow Transplantation.  9 (2003)  2 - p. 97 , 2003
Link: https://doi.org/10.1016/..
 
?
14

Inactivation of infectious pathogens in labile blood compon..:

Corash, L
Transfusion Clinique et Biologique.  8 (2001)  3 - p. 138-145 , 2001
Link: https://doi.org/10.1016/..
 
?
15

Functional Characteristics of S‐59 Photochemically Treated ..:

van Rhenen, D.J. ; Vermeij, J. ; Mayaudon, V....
Vox Sanguinis.  79 (2000)  4 - p. 206-214 , 2000
Link: https://doi.org/10.1046/..
 
1-15